Comparative Pharmacology
Head-to-head clinical analysis: ORTHO TRI CYCLEN versus ORTHO NOVUM 1 50 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO TRI CYCLEN versus ORTHO NOVUM 1 50 28.
ORTHO TRI-CYCLEN vs ORTHO-NOVUM 1/50 28
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combined estrogen-progestin oral contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
Combination oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via estrogen and progestin, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial structure.
FDA-approved: Prevention of pregnancyOff-label: Treatment of acne vulgaris, management of menstrual disorders
Prevention of pregnancy
One tablet (norgestimate 0.180-0.215-0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
One tablet (1 mg norethindrone/50 mcg mestranol) orally once daily for 21 days, followed by 7 days of placebo tablets (inactive) for a 28-day cycle.
None Documented
None Documented
Norethindrone: ~8 hours (terminal). Ethinyl estradiol: ~12-15 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Norethindrone: 5-12 h (mean 8 h); Mestranol: 12-24 h (mean 18 h); steady-state reached within 5-7 days
Ethinyl estradiol: primarily metabolized by CYP3A4; norgestimate: rapidly hydrolyzed to norelgestromin (active) then levonorgestrel, metabolized by CYP3A4 and CYP2C9.
Ethinyl estradiol metabolized via CYP3A4; mestranol (prodrug converted to ethinyl estradiol) and norethindrone metabolized via hepatic reduction and conjugation.
Norethindrone: 60-80% renal (as metabolites), 20-40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Biliary excretion contributes to fecal elimination.
Renal: ~50-60% as metabolites; fecal: ~30-40% as metabolites; biliary: <10%
Norethindrone: ~97% bound to albumin and SHBG. Ethinyl estradiol: ~98% bound to albumin.
Norethindrone: 96-98% (SHBG, albumin); Mestranol: 97-99% (albumin, SHBG with lower affinity)
Norethindrone: 3-4 L/kg (large distribution into tissues, including breast and reproductive tissues). Ethinyl estradiol: 2-3 L/kg (distributes widely).
Norethindrone: 1.5-2.5 L/kg; Mestranol: 0.9-1.5 L/kg; indicates extensive tissue distribution
Norethindrone: ~65% (oral). Ethinyl estradiol: ~40-45% (oral) due to first-pass metabolism.
Oral: norethindrone ~64%; mestranol ~40-70% (first-pass metabolism)
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment (GFR <30 mL/min); use alternative contraception.
No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Insufficient data for severe impairment (CrCl <30 mL/min); avoid use due to potential for fluid retention and hypertension.
Contraindicated in patients with acute hepatitis, cholestatic jaundice of pregnancy or prior OCP use, or severe cirrhosis (Child-Pugh C). Use with caution in Child-Pugh A/B; dose adjustment not defined but consider lower estrogen options.
Contraindicated in severe hepatic disease (Child-Pugh C) or acute liver disease. For mild to moderate impairment (Child-Pugh A or B), use with caution; monitor liver function, no specific dose adjustment guidelines available.
Not indicated in prepubertal children. Postmenarchal adolescents: same dosing as adults. Safety and efficacy not established in children <18 years.
Not indicated in prepubertal girls. Postmenarchal adolescents: same as adult dosing; initiate after menarche and once growth complete.
Not indicated for use after menopause. No specific geriatric dosing; contraindicated in postmenopausal women.
Not indicated for postmenopausal women; no geriatric-specific dosing. Use with caution in older women due to increased risk of thromboembolism and cardiovascular events.
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptive use. Risk increases with age and number of cigarettes smoked, especially in women over 35.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Use is contraindicated in women over 35 years who smoke.
["Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction)","Hepatic neoplasia (benign/malignant)","Gallbladder disease","Hypertension","Carbohydrate/lipid effects","Hereditary angioedema","Chloasma","Retinal thrombosis","Depression"]
Increased risk of thromboembolic disorders, venous thromboembolism (VTE), arterial thrombosis, myocardial infarction, stroke, hepatic neoplasia, and gallbladder disease. Regular monitoring of blood pressure, glucose, and lipid profiles recommended.
["Thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast carcinoma","Undiagnosed abnormal genital bleeding","Pregnancy","Active liver disease or benign/malignant liver tumors","Hypersensitivity to any component","Heavy smoking in women over 35"]
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; pregnancy; hepatic adenoma or carcinoma; jaundice with prior pill use; hypersensitivity to components; women over 35 who smoke.
Data Pending Review
Data Pending Review
No specific food restrictions. Grapefruit may slightly increase estrogen levels; avoid large amounts. Alcohol consumption may increase hepatic toxicity risk; limit to moderate intake.
No significant food interactions. Grapefruit juice may slightly increase estrogen exposure; avoid excessive intake. Taking with food may reduce nausea.
Contraindicated in pregnancy. First trimester: associated with cardiovascular defects and limb reduction defects. Second and third trimesters: no increased risk of major malformations, but may cause fetal harm due to hormonal effects; use only if clearly needed.
Pregnancy category X. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects due to progestin and estrogen exposure. Second and third trimesters: Risk of fetal genital abnormalities (e.g., hypospadias, clitoral hypertrophy), low birth weight, and potential long-term metabolic effects. Use contraindicated in pregnancy.
Small amounts of ethinyl estradiol and norgestimate pass into breast milk; may reduce milk production and composition. M/P ratio not established. Generally avoided during breastfeeding; alternative contraception recommended.
Contraindicated during breastfeeding. Norethindrone and mestranol/metabolites are excreted in breast milk; M/P ratio not established. May reduce milk production and quality, and expose infant to hormonal effects. Recommend alternative contraception.
No dosing adjustments applicable; drug is contraindicated during pregnancy. If used inadvertently, discontinue immediately.
No indication for use in pregnancy; contraindicated. If inadvertent use occurs, discontinue immediately. No pharmacokinetic data to support dose adjustments as drug should not be administered during pregnancy.
Category C
Category C
Contains norgestimate 0.180/0.215/0.250 mg and ethinyl estradiol 0.035 mg. Triphasic regimen mimics natural cycle. Monitor for breakthrough bleeding, especially during first 3 cycles. Use with caution in patients with migraine with aura, hypertension, or history of VTE. Effective for acne vulgaris (FDA-approved indication). Counsel that efficacy may be reduced with concurrent rifampin, certain anticonvulsants, and St. John's wort. Consider switching to monophasic pill if persistent breakthrough bleeding after 3 months.
ORTHO-NOVUM 1/50 28 is a monophasic oral contraceptive containing mestranol 50 µg (a prodrug of ethinyl estradiol) and norethindrone 1 mg. Due to higher estrogen dose, it poses increased risk of venous thromboembolism, especially in smokers over 35. It may reduce the efficacy of lamotrigine. Use with caution in patients with hypertension or liver disease.
Take one pill daily at the same time for 21 days, then placebo pills for 7 days.If you miss a pill within 12 hours, take it as soon as remembered. If more than 12 hours late, use backup contraception (e.g., condoms) for 7 days.Do not smoke while taking this medication; smoking increases risk of blood clots and stroke, especially if over 35.Common side effects: spotting between periods, nausea, breast tenderness, headache. These often improve after a few cycles.Seek emergency medical attention for signs of blood clot: leg pain/swelling, sudden chest pain, difficulty breathing, severe headache, vision changes.This medication does not protect against HIV or other sexually transmitted infections.
Take one tablet daily at the same time, following the package directions for the 28-day regimen.If you miss a pill, follow the instructions in the package insert; use backup contraception if needed.Common side effects include nausea, breast tenderness, and breakthrough bleeding; these often resolve after a few cycles.This medication does not protect against HIV or other sexually transmitted infections.Smoking while using this pill increases your risk of serious cardiovascular side effects; do not smoke.Contact your provider if you experience leg pain, chest pain, shortness of breath, severe headache, or vision changes.